Cart
sales@molnova.com
Zeniplatin
CAS No. 111490-36-9
Zeniplatin( —— )
Catalog No. M34745 CAS No. 111490-36-9
Zeniplatin (Zeniplatinum) is a new cisplatin complex with anticancer activity for the treatment of metastatic melanoma and kidney cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 170 | In Stock |
|
| 10MG | 250 | In Stock |
|
| 25MG | 392 | In Stock |
|
| 50MG | 549 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameZeniplatin
-
NoteResearch use only, not for human use.
-
Brief DescriptionZeniplatin (Zeniplatinum) is a new cisplatin complex with anticancer activity for the treatment of metastatic melanoma and kidney cancer.
-
DescriptionZeniplatin (Zeniplatinum) is a new cisplatin complex with anticancer activity for the treatment of metastatic melanoma and kidney cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number111490-36-9
-
Formula Weight471.36
-
Molecular FormulaC11H20N2O6Pt
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C2(C(=O)[O-][Pt+2]3([O-]1)[NH2]CC(CO)(CO)C[NH2]3)CCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
2,2,14,14-Tetramethy...
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a ketone compound extracted from patent WO2002030860A2, compound example II-9. 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid can be used for the research of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders .
-
CPA inhibitor
CPA inhibitor (Carboxypeptidase inhibitor) is a potent carboxypeptidase A (CPA) inhibitor with a Ki of 0.32 μM.
-
KRA-533
KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells.
